Opportunity ID: 347292
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | HT9425-23-PRCRP-IA |
Funding Opportunity Title: | DoD Peer Reviewed Cancer, Idea Award |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Cooperative Agreement Grant |
Category of Funding Activity: | Science and Technology and other Research and Development |
Category Explanation: | – |
Expected Number of Awards: | 30 |
Assistance Listings: | 12.420 — Military Medical Research and Development |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Apr 04, 2023 |
Last Updated Date: | Apr 04, 2023 |
Original Closing Date for Applications: | Sep 12, 2023 |
Current Closing Date for Applications: | Sep 12, 2023 |
Archive Date: | Oct 12, 2023 |
Estimated Total Program Funding: | $19,200,000 |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
Additional Information on Eligibility: | – |
Additional Information
Agency Name: | Dept. of the Army — USAMRAA |
Description: |
The FY23 PRCRP Idea Award supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research that are relevant to active-duty Service Members, Veterans, other military beneficiaries, and the American public. The advancement of knowledge in cancer research, patient care, and/or treatment options in the MHS is critical to active-duty Service Members, Veterans, other military beneficiaries, and the American public. The intention of the Idea Award is innovative basic research that may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. The Idea Award is not intended to support a logical progression of an already established research project in a laboratory. Incremental advances, the next logical step, or switching a model system from one cancer to another cancer are not considered innovative. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. It is the responsibility of the Principal Investigator (PI) to select the funding opportunity that is most appropriate for the research proposed. Advanced research with robust preliminary data is more appropriate for the FY23 PRCRP Impact Award (HT9425-23-PRCRP-IPA).
Inclusion of preliminary data is discouraged. This award is not intended to support ongoing research in the applicant’s laboratory; therefore, inclusion of preliminary data is not consistent with the exploratory nature of this award. Any preliminary data included in the application will be subjected to evaluated during review and may affect funding recommendations. Preliminary data demonstrating more mature research that is beyond early investigations is discouraged and, if included, may affect funding recommendations. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects to understand the mechanisms of initiation or progression of cancer, the quality of life during and following cancer treatment, etc. |
Link to Additional Information: | – |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
Packages
Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
12.420 | PKG00280971 | Apr 04, 2023 | Sep 12, 2023 | View |